ZYME
Zymeworks Inc.
NASDAQ · Healthcare · Biotechnology · CA
$29.19
−2.37%Year over year
Reported trailing growth
- Revenue
- -69.8%
- EBITDA
- —
- EBIT
- -88.1%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +1163.4%
- EBITDA
- +310.1%
- EPS
- +246.6%
Three-year CAGR
- Revenue
- -36.4%
- EBITDA
- +36.8%
- EBIT
- +32.5%
- Net income
- +33.9%
- EPS
- +33.3%
- Free cash flow
- +69.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026